Crosstalk between the Hippo Pathway and the Wnt Pathway in Huntington's Disease and Other Neurodegenerative Disorders

Cells. 2022 Nov 16;11(22):3631. doi: 10.3390/cells11223631.

Abstract

The Hippo pathway consists of a cascade of kinases that controls the phosphorylation of the co-activators YAP/TAZ. When unphosphorylated, YAP and TAZ translocate into the nucleus, where they mainly bind to the TEAD transcription factor family and activate genes related to cell proliferation and survival. In this way, the inhibition of the Hippo pathway promotes cell survival, proliferation, and stemness fate. Another pathway can modulate these processes, namely the Wnt/β-catenin pathway that is indeed involved in cellular functions such as proliferation and cell survival, as well as apoptosis, growth, and cell renewal. Wnt signaling can act in a canonical or noncanonical way, depending on whether β-catenin is involved in the process. In this review, we will focus only on the canonical Wnt pathway. It has emerged that YAP/TAZ are components of the β-catenin destruction complex and that there is a close relationship between the Hippo pathway and the canonical Wnt pathway. Furthermore, recent data have shown that both of these pathways may play a role in neurodegenerative diseases, such as Huntington's disease, Alzheimer's disease, or Amyotrophic Lateral Sclerosis. Thus, this review analyzes the Hippo pathway and the Wnt pathway, their crosstalk, and their involvement in Huntington's disease, as well as in other neurodegenerative disorders. Altogether, these data suggest possible therapeutic approaches targeting key players of these pathways.

Keywords: Hippo; Huntington’s disease; Wnt; YAP; neurodegeneration.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Hippo Signaling Pathway
  • Humans
  • Huntington Disease*
  • Neurodegenerative Diseases*
  • Protein Serine-Threonine Kinases
  • Wnt Signaling Pathway
  • beta Catenin / metabolism

Substances

  • beta Catenin
  • Protein Serine-Threonine Kinases

Grants and funding

This research received funding from Bonus H from the Centre Hospitalier Universitaire de Lille and the Centre de référence de la maladie de Huntington (C.S.), Inserm, Université de Lille.